Recent highlights from the scientific literature related to a few of my favorite oncology clinical targets: PI3K, HSP90, and ALK... The Structural Basis of PI3K Cancer Mutations: From Mechanism to Therapy. Liu S, Knapp S, Ahmed AA. Abstract While genetic alteration in the p85α-p110α (PI3K) complex represents one of the most frequent driver mutations...

See my recent notes from the Synta presentation of updates ganetespib data at WCLC. Here are more notes from the earnings webcast: Cost of an extra oncology phase 3 patient is $30-40k = so $6-8m for added 200 pts to GALAXY-2 no update on phase 3 enrollment status partnership discussions are "advanced" HDC platform: file an IND within 12-14 months...

Curis $CRIS held in 3q-2013 conference call on November 6 and offered the following updates on their HSP90 inhibitor Debio0932 partnered with Debiopharm. Conference call transcript excerpts c/o SeekingAlpha but have been edited for accuracy. Regarding Debio 0932, I'll give you an update now. We continue to be impressed with our partner, Debiopharm's...

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer Wagner AJ, Chugh R, Rosen LS, Morgan JA, George S, Gordon M, Dunbar J, Normant E, Grayzel D, Demetri GD. INTRODUCTION:The multitargeted tyrosine kinase inhibitor (TKI) crizotinib is active against ALK translocated...

Conference call excerpts from the Ariad Pharma $ARIA 3q-2013 earnings call c/o SeekingAlpha. For 113, we will focus only on ALK-positive lung cancer, both treatment-naive and resistant and those with CNS activity. We will no longer enroll EGFR, T790M, ROS1 or other patients in the ongoing Phase I/II trial. The pivotal registration trial of 113...

See below for a couple of key data slides from the recent Synta Pharma $SNTA update on the ganetespib GALAXY-1 trial in NSCLC. If you missed them, see my recent posts with notes from the data webcast and earnings conference call.